Presentation Information
[2P-847]HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for overcoming drug resistance in EGFR-mutant lung cancer.
○Akihiko Ishimura1, Hanbing Lyu1, Ryusuke Suzuki1, Khurelsukh Buyanbat1, Gerelsuren Batbayar2, Makiko Meguro-Horike3, Shin-ichi Horike3, Hidekazu Tsutsui 4, Seiji Yano5, Takeshi Suzuki1 (1. Cancer Res. Inst., Kanazawa univ., 2. Inst. Biol., Mongolian Academy of Sci., 3. Inst. Liberal Art and Sci., Kanazawa univ., 4. School of Materials Sci., Japan Advanced Inst. Sci. and Tech., 5. Dept. Respiratory Med., Fac. Med. Kanazawa univ.)
Password required to view
Please enter the password printed on your name card.
Online registrants can download your name card from the account page once payment has been successfully processed.
Online registrants can download your name card from the account page once payment has been successfully processed.
Comment
To browse or post comments, you must log in.Log in